Last reviewed · How we verify

NCT06921304: BASEDIET

BASE-DIET: a Study on Nutritional Intervention in Patients With Graves' Disease

Active, enrolled NA Last updated 9 April 2026
What this trial tests

NA trial testing Intensive Lifestyle Intervention in Graves Disease in 54 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
8 January 2024
Primary endpoint
30 September 2026
30 December 2026

Quick facts

Lead sponsorIstituti Clinici Scientifici Maugeri SpA
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment54
Start date8 January 2024
Primary completion30 September 2026
Estimated completion30 December 2026
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituti Clinici Scientifici Maugeri SpA

Who can join

18 and older, any sex, with Graves Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to determine whether a structured dietary-nutritional intervention can prevent excessive weight regain and improve body composition and lifestyle habits in adults recently diagnosed with Graves' disease (Basedow's disease). The main questions it aims to answer are: * Can a dietary intervention prevent patients from regaining more than 1 kg above their pre-disease body weight after restoring euthyroidism? * Does the intervention lead to improvements in body composition, dietary habits, and adherence to the Mediterranean diet? Researchers will compare patients receiving an Intensive Lifestyle Intervention (ILI) including a personalized diet and lifestyle counseling to patients receiving Usual Medical Care (UMC) with general lifestyle advice to see if the dietary intervention results in less weight regain and better metabolic and anthropometric outcomes. Participants will: * Receive antithyroid medication as standard medical care. * Be randomized into either the intervention group (ILI) or control group (UMC). If in the ILI group, participants will: * Receive an individual nutritional consultation within 1 week of enrollment. * Follow a personalized Mediterranean-style low-energy diet. * Attend follow-up visits at 3, 6, 9, and 12 months for: * Dietary adherence and lifestyle assessments. * Anthropometric measurements (weight, BMI, waist/hip circumference). * Bioimpedance analysis (at 6 and 12 months) for body composition. * Dietary intake logs and adherence assessments (3-day food diary). If in the UMC group, participants will: * Receive routine clinical management for Graves' disease. * Complete basic dietary and lifestyle questionnaires at baseline and 12 months. * Undergo anthropometric measurements and bioimpedance at T0 and at the end of study. This study aims to provide evidence on the role of nutritional support in managing weight and metabolic risks in patients undergoing treatment for Graves' disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intensive Lifestyle Intervention

Trials testing the same drug.

Other recruiting trials for Graves Disease

Currently open trials in the same condition.

Other Istituti Clinici Scientifici Maugeri SpA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06921304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing